// Post a message

Replying to:

Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies

Xiaofei Sun, Zijun Zhen, Zhuowei Liu and collaborators from the State Key Laboratory of Oncology in South China and Sun Yat-sen University Cancer Center, Guanghzou China have just published in Cancers the results from their clinical experience with metronomic maintenance in neuroblastoma entitled :Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies Abstract Despite aggressive treatment, the prognosis of (...)

pre-moderation

This forum is moderated beforehand: your contribution will only appear after being validated by a site administrator.

Any message or comment?
  • (To create paragraphs, you simply leave blank lines.)

Who are you? (optional)